

1 **Effectiveness of SARS-CoV-2 Vaccines against Omicron Infection and Severe Events: A Systematic**  
2 **Review and Meta-Analysis of Test-Negative Design Studies**

3  
4 Shangchen Song, MS<sup>1,\*</sup>, Zachary J. Madewell, PhD<sup>1,\*</sup>, Mingjin Liu, PhD<sup>1</sup>, Prof Ira M. Longini, PhD<sup>1,#</sup>,  
5 Prof Yang Yang, PhD<sup>2,#</sup>

6 <sup>1</sup> Department of Biostatistics, College of Public Health and Health professions & Emerging Pathogens  
7 Institute, University of Florida, Gainesville, FL, USA

8 <sup>2</sup> Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA,  
9 USA

10 \* Co-first authors

11 # Co-senior authors

12  
13 Correspondence to: Dr. Yang Yang, Department of Statistics, University of Georgia, 310 Herty Drive,  
14 Athens, GA 30602, USA. [yang.yang4@uga.edu](mailto:yang.yang4@uga.edu)

15 **Abstract**

16 **Background:** Evaluating vaccine effectiveness (VE) of a full vaccine series and booster doses against  
17 COVID-19 is important for health decision-making.

18 **Methods:** We systematically searched papers that evaluated VE of SARS-CoV-2 vaccines on PubMed,  
19 Web of Science, Cochrane Library, Google Scholar, Embase, Scopus, and preprint servers (bioRxiv and  
20 medRxiv) published from November 26th, 2021 to June 27th, 2022 (for full doses and first booster), and  
21 to January 8th, 2023 (for the second booster). The pooled VE against Omicron-associated symptomatic  
22 or any infection as well as severe events are estimated in a meta-analysis framework.

23 **Results:** From 2,552 citations identified, a total of 42 were included. The vaccination of the first booster  
24 provided stronger protection against Omicron than the full doses alone, shown by the VE estimates of  
25 53.1% (95% CI: 48.0–57.8) vs. 28.6% (95% CI: 18.5–37.4) against infection and 82.5% (95% CI:  
26 77.8–86.2) vs. 57.3% (95% CI: 48.5–64.7) against severe disease. The second booster offered strong  
27 protection among adults within 60 days of vaccination against infection (VE=53.1%, 95% CI: 48.0–57.8)  
28 and severe disease (VE=87.3% (95% CI: 75.5-93.4), comparable to the first booster with corresponding  
29 VE estimates of 59.9% against infection and 84.8% against severe disease. The VEs of the booster doses  
30 against severe disease among adults sustained beyond 60 days, 77.6% (95% CI: 69.4–83.6) for the first  
31 and 85.9% (95% CI: 80.3–89.9) for the second booster. The VE against infection was less sustainable  
32 regardless of dose type. Pure mRNA vaccines provided comparable protection to partial mRNA vaccines,  
33 but both provided higher protection than non-mRNA vaccination.

34 **Conclusion:** One or two booster doses of current SARS-CoV-2 vaccines provide considerable protection  
35 against Omicron infection and substantial and sustainable protection against Omicron-induced severe  
36 clinical outcomes.

37 **Funding:** US CDC U01 CK000670

38 **Keywords:** Omicron; Vaccine Effectiveness; Meta-Analysis; Booster Dose; Infection; Severe disease

## 39 Introduction

40 The Omicron variant (B.1.1.529) was first detected in early November 2021 in South Africa and  
41 was designated the fifth variant of concern by the World Health Organization.<sup>1</sup> In contrast to the original  
42 wild-type variant, Omicron accumulated over 50 mutations in the whole genome, including 26-32 in the  
43 spike protein. This altered protein receptor-binding efficiency and immunogenicity, increasing infectivity,  
44 ability to evade neutralizing antibodies, and risk of reinfection.<sup>2</sup> Additional mutations led to multiple  
45 Omicron subvariants with increased transmissibility including BA.2, BA.2.12.1, BA.4, BA.4.6, BA.5,  
46 BF.7, BQ.1, BQ.1.1, and XBB.1.5, the latter three of which accounted for most infections in the United  
47 States as of February, 2023.<sup>3</sup> The effective reproduction number ( $R_t$ ) and basic reproduction number ( $R_0$ )  
48 were estimated to be 3.8 and 2.5 times higher for Omicron than for Delta.<sup>4</sup> Compared with the wild-type  
49 and Delta variants, Omicron replicates less efficiently in the lung parenchymal tissues and more  
50 efficiently in the bronchial tissues, which may contribute to increased transmissibility but decreased  
51 disease severity.<sup>5-7</sup>

52 There is a rapidly growing body of literature of real-world vaccine effectiveness (VE) against  
53 Omicron. Studies reported that individuals vaccinated with two mRNA doses were less susceptible to  
54 Omicron infection, though the level of protection conferred was lower than that of earlier variants, and  
55 protection waned over time.<sup>8,9</sup> The emergence of new variants coupled with waning vaccine-induced  
56 immunity prompted recommendations for booster doses and second booster doses based on the original  
57 vaccine formula, which were shown to confer greater protection against Omicron than two mRNA  
58 doses.<sup>10,11</sup> Omicron-specific bivalent mRNA booster doses were recently authorized for use in the U.S. by  
59 the Food and Drug Administration, and early data demonstrated stronger neutralizing antibody responses  
60 against Omicron than the original monovalent mRNA vaccines.<sup>12</sup> The BNT162b2 bivalent BA.4/5  
61 COVID-19 vaccine was recently shown to elicit greater neutralizing antibody titers against newer  
62 Omicron sublineages (BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1) in adults older than 55 than a fourth dose  
63 of the original monovalent BNT162b2.<sup>13</sup> Uptake of the bivalent boosters, however, is low with only 15%

64 of the U.S. adult population vaccinated as of February 2023.<sup>14</sup> Therefore, it is important to quantify the  
65 effectiveness of the original vaccines against Omicron.

66 Two early meta-analyses evaluated VE of a primary vaccine series or single booster dose and  
67 demonstrated greater protection for the third dose against symptomatic infection and severe events  
68 compared to a two-dose regimen.<sup>15,16</sup> However, they focused on hybrid immunity (immunity developed  
69 from SARS-CoV-2 infection and vaccination)<sup>15</sup> and relative vaccine effectiveness of the third dose  
70 compared to two doses<sup>16</sup> rather than non-vaccination. Nor did they evaluate VE for a second booster,  
71 long-term (>60 days) VE for the first booster, or adult- and child-specific VEs. Herein, we aggregate  
72 estimates in the literature to evaluate VE for the initial full doses, first booster dose, and second booster  
73 dose against Omicron-related infection and severe events for pure mRNA, partial (mixed) mRNA, and  
74 non-mRNA vaccines. We focus our review on test-negative design studies, an increasingly popular  
75 epidemiological study design for evaluating VE on infectious pathogens including influenza, rotavirus,  
76 pneumococcus, and others.<sup>17</sup> In this design, the same clinical definition is used to enroll cases and  
77 controls and laboratory testing distinguishes “test positive” cases from “test negative” controls, thereby  
78 reducing bias from differential healthcare-seeking behavior between cases and controls.<sup>18</sup>

79

## 80 **Methods**

### 81 *Data sources, eligibility criteria, search strategies, and data extraction*

82 This analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses  
83 (PRISMA) reporting guidelines. A systematic literature search was conducted of PubMed, Web of  
84 Science, Cochrane Library, Google Scholar, Embase, Scopus, and preprint servers (bioRxiv and  
85 medRxiv) for papers published from November 26th, 2021, when Omicron was classified as a World  
86 Health Organization Variant of Concern,<sup>1</sup> to June 27th, 2022 (for full doses and booster), and to January  
87 8th, 2023 (for the second booster).

88 The selection of studies followed Participant (P), Intervention (I), Comparator (C), Outcome (O),  
89 and Study Type (S), PICOS criteria<sup>19</sup> (supplementary materials p 2). Published studies were eligible for

90 inclusion if they were original analyses with the test-negative design and reported VE or corresponding  
91 odds ratios (OR) of full doses, booster, or second booster against Omicron infection or severe events. We  
92 excluded studies that focused on special populations (e.g., patients with kidney disease); did not include  
93 circulation period of Omicron variant; combined VE estimates for Omicron with other viral variants such  
94 as Delta; reported relative VE between different vaccines, vaccination doses, or variants among  
95 vaccinated individuals; did not evaluate VE (e.g., instead, evaluated neutralizing antibodies); or evaluated  
96 outcomes other than infection or severe events. All available ages were included. We did not contact  
97 authors for additional data.

98 We applied Boolean combinations of the following keywords to identify relevant publications:  
99 “SARS-CoV-2”, “COVID-19”, “2019nCoV”, “vaccine”, “booster”, “second booster”, “effectiveness”,  
100 “efficacy”, “test-negative case-control”, “test-negative design”, “Omicron”, “infection”, “hospitalization”;  
101 the detailed search procedures were presented in the supplementary materials. Publication language was  
102 not restricted, and reference lists of selected papers were also screened for additional studies.

103 After removing duplicated results, we first screened studies by titles and abstracts to identify  
104 potentially eligible articles. Two pairs of researchers then independently evaluated full texts and selected  
105 those meeting the inclusion criteria. Any disagreements were discussed until a consensus was reached.  
106 Preprints were checked and updated with their most recent published version if available as of January  
107 10<sup>th</sup>, 2023. Zotero was used for literature management. Finally, two pairs of researchers independently  
108 extracted the following from the included studies: author names, publication year, study region, study  
109 design, dose, vaccine type, test time in reference to vaccination time, adjusted VE point estimate and 95%  
110 confidence intervals, and adjustment confounders; if available, the number of vaccinated and  
111 unvaccinated individuals in the cases and controls were also recorded.

112

### 113 *Evaluation of study quality and risk of bias*

114 Study quality and risk of bias were independently assessed by two researchers using the  
115 Newcastle-Ottawa Scale (NOS). Studies could earn up to 9 points composed of participant selection (4

116 points), study comparability (1 point), and outcome of interest (4 points). A score >7 was considered as  
117 high quality, 5–6 as medium, and <5 as low, and studies classified as low were excluded from the meta-  
118 analysis. Publication bias was also evaluated by Egger’s test, Begg and Mazumdar rank correlation, and  
119 funnel plots when at least ten studies were available, with significance set at  $p < 0.1$ . If we detected  
120 publication bias, we used the Duval and Tweedie trim-and-fill method<sup>20</sup> for adjustment, which consists of  
121 imputing missing effect sizes to achieve symmetry.

122

### 123 *Statistical analysis*

124 We categorized full doses and booster VE into short-term, long-term, and overall to evaluate  
125 potential waning of VE over time. There is no uniform definition for short-term vs. long-term VE, but  
126 most studies adopted cut-off points of 60-120 days from last vaccination to lab-testing. We used these  
127 cut-off points to guide the classification of VE estimates into short-term vs. long-term (supplementary  
128 materials p 2). If a study reported VEs for finer time intervals than we needed, we used an inverse  
129 variance-weighted (IVW) averaging approach to combine them.

130 For each time interval, we further categorized VE by the type of vaccine: pure mRNA vaccines,  
131 partial mRNA vaccines, and non-mRNA vaccines. Pure mRNA vaccines comprise of homogenous or  
132 heterogeneous BNT162b2 and mRNA-1273, or a population-level mixture of the two if a study does not  
133 discriminate between them. Partial mRNA vaccines include either a multi-dose course containing at least  
134 one mRNA vaccine dose, or the study indiscriminately reported VEs of a population-level mixture of  
135 vaccines including at least one mRNA vaccine. Non-mRNA vaccines refers to the regimens that do not  
136 involve mRNA vaccines at all (e.g., Ad26.COV2.S, ChAdOx1).

137 We evaluated VE against Omicron infection and severe events. Analyses of VE against infection  
138 or symptomatic infection combined studies that reported either VE against symptomatic infection or VE  
139 against any infection (symptomatic or asymptomatic). Severe events included hospitalizations, noncritical  
140 hospitalizations, deaths, emergency department (ED) or urgent care (UC) encounters, ED admissions,  
141 intensive care unit (ICU) admissions, and invasive ventilation.

142 We evaluated VE for the overall vaccine-eligible population as well as for age groups defined as  
143 adults ( $\geq 18$  years) and children/adolescents (5-17 years). If VE was not reported but odds ratios (OR)  
144 were provided, we calculated VE as  $(1 - OR) \times 100\%$ . The pooled VE and 95% confidence intervals were  
145 calculated via a random effects meta-analysis with restricted maximum likelihood estimation.  $I^2$  was used  
146 to evaluate between-study heterogeneity with thresholds of 25%, 50%, and 75% indicating low, moderate,  
147 and high heterogeneity, respectively. The metafor package in the R statistical software (version 4.0.5) was  
148 used for estimation and visualization in this meta-analysis.<sup>21</sup>

149

#### 150 *Role of the funding source*

151 The funders had no role in study design, data collection, data analysis, data interpretation, or the  
152 writing of the report.

153

#### 154 **Results**

155 For full doses and booster doses, we obtained 1,139 articles from all searched databases (82 from  
156 PubMed, 23 from Web of Science, 89 from Embase, 721 from Scopus, 3 from Cochrane Library, 115  
157 from medRxiv, 6 from bioRxiv, and 100 from Google Scholar). After removing duplicates, 952 articles  
158 remained, of which 136 were retained for full review following inspection of the title, abstract, and  
159 keywords. After full text review of these 136 articles, 33<sup>9,22-53</sup> with 271 VE estimates were formally  
160 included in this meta-analysis (supplementary materials p 18). For the second booster, we obtained 1,413  
161 articles from all databases (56 from PubMed, 22 from Web of Science, 55 from Embase, 1,015 from  
162 Scopus, nine from Cochrane Library, 149 from medRxiv, seven from bioRxiv, and 100 from Google  
163 Scholar). After removing duplicates, 1,236 articles remained, of which 116 were considered relevant after  
164 inspection of the title, abstract, and keywords. These 116 relevant articles were then reviewed in full text  
165 for eligibility, and 11 articles<sup>23,37,54-62</sup> with 46 VE estimates were finally included in this meta-analysis  
166 (supplementary materials p 19). More summary details and detected publication bias of the included  
167 studies are given in the supplementary materials (p 2).

168 The VE estimates for the initial full doses against Omicron symptomatic infection or any  
169 infection were summarized in Figure 1. Pooling all vaccine types and time intervals, the overall VE was  
170 estimated to be 28.6% (95% CI: 18.5-37.4%, 25 studies) for all ages and 24.4% (95% CI: 16.2-31.8%, 15  
171 studies) for adults. Overall VE of the pure mRNA vaccines was estimated to be 30.6% (95% CI: 17.1-  
172 41.8%, 18 studies) for all ages, 25.4% (95% CI: 11.5-37.1%, 8 studies) for adults, and 54.2% (95% CI:  
173 35.2-67.7%, 5 studies) for children and adolescents. Overall VE estimates for partial mRNA vaccines and  
174 non-mRNA vaccines were only available for adults, 28.1% (95% CI: 19.8-35.6%, 5 studies) and 1.5%  
175 (95% CI: 0.4-2.7%, 2 studies) respectively. This is also why we do not have a separate overall VE  
176 estimate for children and adolescents pooling all vaccine types.

177 Short-term full-dose VE estimates pooling all vaccine types were 40.7% (95% CI: 34.3-46.5%,  
178 19 studies) for all ages and 37.5% (95% CI: 31.4-43.1%, 10 studies) for adults (supplementary materials p  
179 3). Short-term VE of pure mRNA vaccines was estimated to be 43.5% (95% CI: 35.4-50.6%, 13 studies)  
180 for all ages, 41.3% (95% CI: 40.2-42.4%, 4 studies) for adults, and 45.3% (95% CI: 28.7-58.1%, 6  
181 studies) for children and adolescents. Short-term VE estimate of partial mRNA vaccines was 34.7% (95%  
182 CI: 25.4-42.9%, 6 studies) for adults, slightly lower than that of the pure mRNA vaccines.

183 Long-term full-dose VE estimates against symptomatic or any infection were in general much  
184 lower than their short-term counterparts. Pooling all vaccine types, long-term full-dose VE was estimated  
185 to be 17.6% (95% CI: 13.2-21.8%, 22 studies) for all ages and 16.6% (95% CI: 10.5-22.3%, 15 studies)  
186 for adults (supplementary materials p 4). Long-term full-dose VE of pure mRNA vaccines was estimated  
187 to be 16.4% (95% CI: 13.6-19.1%, 11 studies) for all ages, 13.1% (95% CI: 11.7-14.6%, 4 studies) for  
188 adults, and 22.3% (95% CI: 13.6-30.1%, 4 studies) for children and adolescents. Long-term full-dose VE  
189 among adults was estimated to be 22.6% (95% CI: 10.8-32.7%, 5 studies) for partial mRNA vaccines and  
190 13.2% (95% CI: 2.6-22.6%, 6 studies) for non-mRNA vaccines.

191 Compared to unvaccinated controls, the overall VE of the first booster dose against Omicron  
192 symptomatic infection or any infection was 53.1% (95% CI: 48.0-57.8%, 31 studies) for all ages and  
193 53.4% (95% CI: 47.7-58.6%, 27 studies) for adults (Figure 2). No studies included in this analysis

194 reported VE of booster doses for children. When stratified by vaccine type, the overall first-booster VE  
195 estimates were 58.0% (95% CI: 51.4-63.6%, 11 studies) for all ages and 61.4% (95% CI: 54.1-67.5%, 7  
196 studies) in adults for pure mRNA vaccination, 56.4% (95% CI: 52.7-59.8%, 15 studies) for adults for  
197 partial mRNA vaccines, and 25.2% (95% CI: 2.2-42.8%, 5 studies) for adults for non-mRNA vaccines,

198 In comparison to its overall VE, the short-term VE estimates of the first booster dose were  
199 slightly higher, 59.4% (95% CI: 55.1-63.3%, 33 studies) for all ages and 59.9% (95% CI: 55.1-64.1%, 28  
200 studies) for adults (supplementary materials p 5). When stratified by vaccine type, the short-term first-  
201 booster VE estimates were 63.7% (95% CI: 59.2-67.7%, 15 studies) for all ages and 67.3 % (95% CI:  
202 64.5-69.9%, 10 studies) for adults for pure mRNA vaccination, 62.3% (95% CI: 59.2-65.1%, 12 studies)  
203 for adults for partial mRNA vaccines, and 37.2% (95% CI: 19.5-51.0%, 6 studies) for adults for non-  
204 mRNA vaccines.

205 Long-term VE estimates of the first booster dose were moderately lower than their overall  
206 counterparts, 34.9% (95% CI: 27.6-41.5%, 22 studies) for all ages and 31.5% (95% CI: 22.7-39.4%, 20  
207 studies) for adults (supplementary materials p 6). Long-term first-booster VE estimates stratified by  
208 vaccine type were 46.6% (95% CI: 36.8-54.8%, 7 studies) for all ages and 50.9% (95% CI: 45.0-56.2%, 5  
209 studies) for adults for pure mRNA vaccination, 34.6% (95% CI: 28.6-40.2%, 11 studies) for adults for  
210 partial mRNA vaccines, and 4.6% (95% CI: -9.5-16.9%, 4 studies) for adults for non-mRNA vaccines.

211 Due to lack of data, we were only able to estimate short-term and long-term VE but not overall  
212 VE of the second booster (Figure 3). Furthermore, we were unable to distinguish between vaccine types  
213 for the second booster, but the majority of these studies were based on four doses of mRNA vaccines. The  
214 short-term second-booster VE against symptomatic infection or any infection for Omicron was 59.6%  
215 (95% CI: 52.0-66.1%, 17 studies) in adults, similar to the overall and the short-term first-booster VE  
216 estimates in adults. The long-term second-booster VE was 32.7% (95% CI: 15.4-46.4%, 10 studies) in  
217 adults, comparable to that of the first booster.

218 Overall VE of the full doses against Omicron-associated severe events was estimated to be 57.3%  
219 (95% CI: 48.5%-64.7%, 24 studies) for all ages and 57.9% (95% CI: 51.5%-63.4%, 16 studies) for adults

220 (Figure 4). Overall VE estimates of pure mRNA vaccines were 60.9% (95% CI: 50.7-68.9%, 18 studies)  
221 for all ages, 60.1% (95% CI: 53.1-66.0%, 10 studies) for adults, and 59.9% (95% CI: 24.7-78.6%, 6  
222 studies) for children and adolescents. Overall VE of partial mRNA vaccines for adults was slightly lower  
223 than that of pure mRNA vaccines, 54.5% (95% CI: 41.1-64.8%, 6 studies). We did not find studies  
224 estimating the overall VE of non-mRNA vaccines against Omicron-related severe events.

225 Short-term VE of the full doses against Omicron-associated severe events was estimated to be  
226 66.9% (95% CI: 58.3-73.8%, 16 studies) for all ages and 69.9% (95% CI: 62.8-75.6%, 10 studies) for  
227 adults (supplementary materials p 7). Stratified by vaccine type, the short-term VE estimates were 64.0%  
228 (95% CI: 50.2-74.0%, 9 studies) for all ages, 70.5% (95% CI: 64.9-75.2%, 3 studies) for adults, 60.7%  
229 (95% CI: 36.6%-75.6%, 6 studies) for children and adolescents for pure mRNA vaccines and 70.7% (95%  
230 CI: 59.2%-78.9%, 7 studies) for adults for partial mRNA vaccines.

231 Long-term VE estimates of the full doses against Omicron-associated severe events were  
232 comparable to the overall VE estimates, 58.3% (95% CI: 45.5-68.1%, 18 studies) for all ages and 59.0%  
233 (95% CI: 49.0-67.1%, 13 studies) for adults (supplementary materials p 8). Stratified by vaccine type, the  
234 long-term VE estimates were 62.4% (95% CI: 38.9-76.8%, 9 studies) for all ages, 67.7% (95% CI: 56.3-  
235 76.1%, 4 studies) for adults, and 56.4% (95% CI: -3.6-81.7%, 5 studies) for children and adolescents for  
236 pure mRNA vaccines, 50.7% (95% CI: 29.9-65.2%, 6 studies) for adults for partial mRNA vaccines, and  
237 60.1% (95% CI: 39.7-73.6%, 3 studies) for adults for non-mRNA vaccines.

238 First booster doses generally showed higher VEs against Omicron-associated severe disease than  
239 full doses. The pooled overall VE of the first booster dose was estimated to be 82.5% (95% CI: 77.8%-  
240 86.2%, 28 studies) for all ages and 82.0% (95% CI: 77.0%-86.0%, 25 studies) for adults (Figure 5). Pure  
241 mRNA vaccines and partial mRNA vaccines showed similar overall VEs against severe events, 83.6%  
242 (95% CI: 77.0-88.2%, 11 studies) for all ages, 82.5% (95% CI: 74.7-88.0%, 8 studies) for adults for the  
243 former, and 84.6% (95% CI: 77.6%-89.5%, 12 studies) for adults for the latter. Overall VE was  
244 moderately lower for non-mRNA vaccines, 71.4% (95% CI: 52.1-82.9%, 5 studies) for adults.

245 Short-term and long-term VEs of the booster dose against Omicron-associated severe events were  
246 only available for adults (supplementary materials p 9). We estimated short-term VE to be 84.8% (95%  
247 CI: 80.4-88.1%, 17 studies) and long-term VE to be 77.6% (95% CI: 69.4-83.6%, 16 studies) for all  
248 vaccine types combined. Short-term vs. long-term booster VE estimates were 85.3% (95% CI: 79.8%-  
249 89.3%, 6 studies) vs. 80.1% (95% CI: 64.6-88.8%, 5 studies) for pure mRNA vaccines, 88.1% (95% CI:  
250 83.4-91.4%, 7 studies) vs. 78.0% (95% CI: 64.3-86.4%, 8 studies) for partial mRNA vaccines, and  
251 73.0% (95% CI: 53.7-84.3%, 4 studies) vs. 70.5% (95% CI: 47.3-83.5%, 3 studies) for non-mRNA  
252 vaccines.

253 Pooled short-term and long-term VE estimates for the second booster against Omicron-associated  
254 severe events among adults were 87.3% (95% CI: 75.5-93.4%, 14 studies), and 85.9% (95% CI: 80.3-  
255 89.9%, 5 studies) respectively (Figure 3), both of which are comparable to those of the first booster,  
256 though the long-term VE of the second booster appears to decay at a slower rate.

257

## 258 **Discussion**

259 In this systematic review and meta-analysis of 42 studies, we found that one or two booster doses  
260 in addition to the initial full COVID-19 vaccine series provided substantial protection against Omicron  
261 infection with VE  $\geq$  50% and severe events with VE  $\geq$  80%, compared to no vaccination. In general, pure  
262 and partial mRNA vaccines provided comparable protection levels against infection or severe disease, and  
263 both were more effective than non-mRNA vaccines, though the difference was less dramatic in terms of  
264 protection against severe disease. The VEs of the full doses and the booster doses against severe disease  
265 only wane slightly after three months, but the VEs against infection wane more quickly.

266 Both the first and second booster doses provided considerably higher VE against infection and  
267 severe events compared to completion of the initial full series only. Studies have reported higher anti-  
268 receptor binding domain specific memory B cells and anti-spike antibodies after booster doses compared  
269 to full series only.<sup>23,63</sup> Similarly, T cell immunity against Omicron is provided by booster doses though at  
270 a reduced level compared to ancestral variants.<sup>64</sup> While the initial full doses provided inadequate

271 protection against infection (Figure 1), they did render practically meaningful ( $\geq 50\%$ ) VE against severe  
272 disease (Figure 4).

273 Pure and partial mRNA vaccines offered comparable protection levels against infection, 25.4%  
274 vs. 28.1% for the full doses and 61.4% vs. 56.4% for the first booster among adults, and both were much  
275 more effective than the non-mRNA vaccines (1.5% for the full doses and 25.2% for the first booster).  
276 Studies included in this analysis reported lower binding activities between anti-spike and anti-receptor  
277 among Ad26.COVID recipients compared to mRNA recipients.<sup>23</sup> Similar trends were observed against  
278 severe events, though the gap between mRNA and non-mRNA vaccines was much narrower. In  
279 particular, full-dose non-mRNA vaccines provided a similar level of sustained protection against severe  
280 disease (VE=60%) compared to full-dose mRNA vaccines (supplementary materials p 8), suggesting that  
281 the initial full doses of non-mRNA vaccines should be encouraged among unvaccinated individuals in  
282 regions where mRNA vaccine supply is insufficient.

283 The VEs of the initial full doses and the first booster dose against Omicron infection waned  
284 substantially over time, from 40.7% within three months of boosting to 17.6% for full doses and 59.4% to  
285 34.9% for the first booster. The VEs against Omicron-associated severe disease waned at a slower pace,  
286 from 66.9% to 58.3% for the full doses and from 84.8% to 77.6% (in adults) for the first booster dose.  
287 Our findings are consistent with other studies reporting waning immunity of COVID-19 vaccines for  
288 earlier variants<sup>19, 59</sup> as well as for Omicron regardless of age, immunocompromised status, and vaccine  
289 product.<sup>56</sup> One study reported that VE against symptomatic infection waned more rapidly among older  
290 adults,<sup>65</sup> which was also reflected in this meta-analysis, e.g., the full-dose VE of pure mRNA vaccines  
291 against infection declined from 45.3% to 22.3% among children and from 41.3% to 13.1% among adults  
292 (supplementary materials pp 3-4). These age differences in decay rates were not observed for the VEs  
293 against severe disease (supplementary materials pp 7-8).

294 The second booster of pure or partial mRNA vaccines protected adults from Omicron infection  
295 with a VE of 59.6% which is slightly lower than the short-term VE of the first booster for pure mRNA  
296 (67.3%) or partial mRNA vaccines (62.3%) among adults. A similar gap was seen for the long-term VE

297 among adults as well, 32.7% for the second booster vs. 50.9% for pure mRNA and 34.6% for partial  
298 mRNA first boosters. This seemingly unexpected gap (not statistically significant) may result from the  
299 fact that the dominant Omicron subvariants were mostly BA.1 and BA.2 for the first booster studies but  
300 BA.4 and BA.5 were taking over for the second booster studies. BA.4 and BA.5 are known to be  
301 associated with high immune escape and transmissibility compared to BA.1 and BA.2, e.g., the effective  
302 reproductive number was estimated to be 5.11 and 5.22 for BA.4 and BA.5 compared to 3.22 and 5.04 for  
303 BA.1 and BA.2.<sup>66</sup>

304 In terms of protection against severe disease among adults, we observed comparable VE  
305 estimates between the second booster and the first booster doses for both short term (87.3% for the second  
306 booster vs. 85.3% and 88.1% for pure and partial mRNA first boosters) and long term (85.9% for second  
307 booster vs. 80.1% and 78.0 for pure and partial mRNA first boosters). The second booster appears to  
308 wane to a lesser extent over time. However, a caveat is that nearly all data used to estimate the long-term  
309 VE of the second booster against severe disease came from the same study among elderly residents of  
310 long-term care facilities in Ontario, Canada.<sup>61</sup> In addition, this long-term VE is against BA.1 and BA.2,  
311 the dominant subvariants during the study period of 31 Dec 2021 to 27 April 2022, according to the  
312 Ontario Ministry of Health.

313 Our study had several limitations. First, in several test-negative studies, we included, the same  
314 control group for multiple vaccine groups, which introduces dependence among the VE estimates.  
315 However, such dependence was not accounted for in our analysis due to lack of covariance estimates.  
316 Second, there was significant heterogeneity in VE estimates, which may be attributable to differences  
317 between studies in terms of a whole host of characteristics, including study design, follow-up duration,  
318 definitions of VE, time since vaccination, dosing intervals, confounders adjusted for, and others.

319 Our findings demonstrate that completion of a full COVID-19 vaccine series plus one or two  
320 booster doses provides considerable VE against Omicron infection and strong VE against severe events  
321 compared to non-vaccination. Although VEs generally wane after 2-3 months, the second booster clearly  
322 generates more sustainable protection. To facilitate comparison and synthesis of VE estimates across

323 studies, we recommend the following improvements to future vaccine studies: (1) longer follow-up to  
324 better understand long-term VE; (2) stratification of VE by age group and vaccine type whenever  
325 possible; and (3) when multiple VE estimates are reported, providing covariance or correlation among the  
326 estimates via, e.g., resampling the data.

327

### 328 **Contributor**

329 YY and IL conceived the study. SS, ZM and ML collected the data, SS, ZM, ML and YY  
330 reviewed the data. SS analyzed data under the supervision of YY, ZM and IL. SS, ZM and YY drafted the  
331 manuscript. All authors contributed to interpretation of results and critical revision.

### 332 **Conflicts of interest**

333 We declare that we have no conflicts of interest.

### 334 **Acknowledgements**

335 YY, IL and SS were supported by the US CDC grant (U01 CK000670).

336

### 337 **References**

- 338 1 World Health Organization. Tracking SARS-CoV-2 variants. 2022.  
339 <https://www.who.int/activities/tracking-SARS-CoV-2-variants>.
- 340 2 Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-  
341 CoV-2 Omicron variant. *J Med Virol* 2022; **94**: 2376–83.
- 342 3 Centers for Disease Control and Prevention. Monitoring Variant Proportions. 2022.  
343 <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>.
- 344 4 Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is  
345 several times relative to Delta. *Journal of Travel Medicine* 2022; **29**: taac037.
- 346 5 Hui KP, Ng K-C, Ho JC, *et al*. Replication of SARS-CoV-2 Omicron BA. 2 variant in ex vivo cultures  
347 of the human upper and lower respiratory tract. *EBioMedicine* 2022; **83**: 104232.
- 348 6 Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique  
349 SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA Network Open* 2022; **5**:  
350 e2228008–e2228008.
- 351 7 Nyberg T, Ferguson NM, Nash SG, *et al*. Comparative analysis of the risks of hospitalisation and  
352 death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England:  
353 a cohort study. *The Lancet* 2022; **399**: 1303–12.

- 354 8 Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household secondary attack rates of  
355 SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.  
356 *JAMA network open* 2022; **5**: e229317–e229317.
- 357 9 Ferdinands JM, Rao S, Dixon B, *et al* Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines  
358 Against COVID-19–Associated Emergency Department and Urgent Care Encounters and  
359 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance —  
360 VISION Network, 10 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022a; **71**.  
361 DOI:10.15585/mmwr.mm7107e2.
- 362 10 Tenforde MW, Self WH, Gaglani M, *et al*. Effectiveness of mRNA Vaccination in Preventing  
363 COVID-19–Associated Invasive Mechanical Ventilation and Death—United States, March 2021–  
364 January 2022. *Morbidity and Mortality Weekly Report* 2022; **71**: 459.
- 365 11 Arashiro T, Arima Y, Muraoka H, *et al*. COVID-19 vaccine effectiveness against symptomatic SARS-  
366 CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center  
367 prospective case-control study (FASCINATE study). *Clinical Infectious Diseases* 2022; : ciac635-.
- 368 12 Chalkias S, Harper C, Vrbicky K, *et al*. A bivalent Omicron-containing booster vaccine against  
369 COVID-19. *New England Journal of Medicine* 2022; **387**: 1279–91.
- 370 13 Fang Z, Monteiro VS, Hahn AM, Grubaugh ND, Lucas C, Chen S. Bivalent mRNA vaccine booster  
371 induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5. *Cell*  
372 *Discov* 2022; **8**: 1–4.
- 373 14 CDC. COVID Data Tracker. Centers for Disease Control and Prevention. 2020; published online  
374 March 28. <https://covid.cdc.gov/covid-data-tracker> (accessed Feb 6, 2023).
- 375 15 Bobrovitz N, Ware H, Ma X, *et al*. Protective effectiveness of previous SARS-CoV-2 infection and  
376 hybrid immunity against the omicron variant and severe disease: a systematic review and meta-  
377 regression. *The Lancet Infectious Diseases* 2023; published online Jan 18. DOI:10.1016/S1473-  
378 3099(22)00801-5.
- 379 16 Pratama NR, Wafa IA, Budi DS, *et al*. Effectiveness of COVID-19 Vaccines against SARS-CoV-2  
380 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression.  
381 *Vaccines* 2022; **10**: 2180.
- 382 17 Chua H, Feng S, Lewnard JA, *et al*. The Use of Test-negative Controls to Monitor Vaccine  
383 Effectiveness: A Systematic Review of Methodology. *Epidemiology* 2020; **31**: 43.
- 384 18 Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design  
385 for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016; **184**: 345–53.
- 386 19 Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and  
387 SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative  
388 systematic reviews. *BMC Health Serv Res* 2014; **14**: 579.
- 389 20 Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for  
390 publication bias in meta-analysis. *Biometrics* 2000; **56**: 455–63.

- 391 21 Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of statistical*  
392 *software* 2010; **36**: 1–48.
- 393 22 Accorsi EK, Britton A, Fleming-Dutra KE, *et al.* Association Between 3 Doses of mRNA COVID-19  
394 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA*  
395 2022; **327**: 639–51.
- 396 23 Adams K, Rhoads JP, Surie D, *et al.* Vaccine effectiveness of primary series and booster doses against  
397 covid-19 associated hospital admissions in the United States: living test negative design study. *BMJ*  
398 2022; **379**: e072065.
- 399 24 Altarawneh HN, Chemaitelly H, Ayoub HH, *et al.* Effects of Previous Infection and Vaccination on  
400 Symptomatic Omicron Infections. *New England Journal of Medicine* 2022; **387**: 21–34.
- 401 25 Andeweg SP, de Gier B, Eggink D, *et al.* Protection of COVID-19 vaccination and previous infection  
402 against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. *Nature Communications* 2022; **13**:  
403 4738.
- 404 26 Andrews N, Stowe J, Kirsebom F, *et al.* Covid-19 Vaccine Effectiveness against the Omicron  
405 (B.1.1.529) Variant. *New England Journal of Medicine* 2022; **386**: 1532–46.
- 406 27 Braeye T, Loenhout J van, Brondeel R, *et al.* COVID-19 Vaccine effectiveness against symptomatic  
407 infection and hospitalization in Belgium, July 2021-APRIL 2022. 2022; : 2022.05.09.22274623.
- 408 28 Buchan SA, Chung H, Brown KA, *et al.* Estimated Effectiveness of COVID-19 Vaccines Against  
409 Omicron or Delta Symptomatic Infection and Severe Outcomes. *JAMA Network Open* 2022a; **5**:  
410 e2232760.
- 411 29 Buchan SA, Nguyen L, Wilson SE, Kitchen SA, Kwong JC. Vaccine Effectiveness of BNT162b2  
412 Against Delta and Omicron Variants in Adolescents. *Pediatrics* 2022b; **150**: e2022057634.
- 413 30 Carazo S, Skowronski DM, Brisson M, *et al.* Protection against omicron (B.1.1.529) BA.2 reinfection  
414 conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care  
415 workers with and without mRNA vaccination: a test-negative case-control study. *The Lancet Infectious*  
416 *Diseases* 2022; published online Sept 21. DOI:10.1016/S1473-3099(22)00578-3.
- 417 31 Chemaitelly H, Ayoub HH, AlMukdad S, *et al.* Duration of mRNA vaccine protection against SARS-  
418 CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. *Nat Commun* 2022; **13**: 3082.
- 419 32 Chin ET, Leidner D, Lamson L, *et al.* Protection against Omicron conferred by mRNA primary  
420 vaccine series, boosters, and prior infection. 2022; : 2022.05.26.22275639.
- 421 33 Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine against  
422 Omicron Variant in South Africa. *New England Journal of Medicine* 2022; **386**: 494–6.
- 423 34 Fleming-Dutra KE, Britton A, Shang N, *et al.* Association of Prior BNT162b2 COVID-19 Vaccination  
424 With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron  
425 Predominance. *JAMA* 2022; **327**: 2210–9.

- 426 35 Florentino PTV, Millington T, Cerqueira-Silva T, *et al.* Vaccine effectiveness of two-dose BNT162b2  
427 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a  
428 test-negative case-control study. *The Lancet Infectious Diseases* 2022; **22**: 1577–86.
- 429 36 Gray G, Collie S, Goga A, *et al.* Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against  
430 Omicron Variant in South Africa. *New England Journal of Medicine* 2022; **386**: 2243–5.
- 431 37 Grewal R, Kitchen SA, Nguyen L, *et al.* Effectiveness of a fourth dose of covid-19 mRNA vaccine  
432 against the omicron variant among long term care residents in Ontario, Canada: test negative design  
433 study. *BMJ* 2022a; **378**: e071502.
- 434 38 Kim SS, Chung JR, Talbot HK, *et al.* Effectiveness of two and three mRNA COVID-19 vaccine doses  
435 against Omicron- and Delta-Related outpatient illness among adults, October 2021–February 2022.  
436 *Influenza Other Respir Viruses* 2022; **16**: 975–85.
- 437 39 Kirsebom FCM, Andrews N, Stowe J, *et al.* COVID-19 vaccine effectiveness against the omicron  
438 (BA.2) variant in England. *The Lancet Infectious Diseases* 2022a; **22**: 931–3.
- 439 40 Kirsebom FCM, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal J. Effectiveness of  
440 ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. *Nat*  
441 *Commun* 2022b; **13**: 7688.
- 442 41 Klein NP, Stockwell MS, Demarco M, *et al.* Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2  
443 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care  
444 Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–  
445 17 Years — VISION Network, 10 States, April 2021–January 2022. *MMWR Morb Mortal Wkly Rep*  
446 2022; **71**. DOI:10.15585/mmwr.mm7109e3.
- 447 42 Lauring AS, Tenforde MW, Chappell JD, *et al.* Clinical severity of, and effectiveness of mRNA  
448 vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:  
449 prospective observational study. *BMJ* 2022; **376**: e069761.
- 450 43 Lind ML, Robertson AJ, Silva J, *et al.* Effectiveness of Primary and Booster COVID-19 mRNA  
451 Vaccination against Omicron Variant SARS-CoV-2 Infection in People with a Prior SARS-CoV-2  
452 Infection. 2022; : 2022.04.19.22274056.
- 453 44 Natarajan K, Prasad N, Dascomb K, *et al.* Effectiveness of Homologous and Heterologous COVID-19  
454 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against  
455 COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations  
456 Among Adults — VISION Network, 10 States, December 2021–March 2022. *MMWR Morb Mortal*  
457 *Wkly Rep* 2022; **71**. DOI:10.15585/mmwr.mm7113e2.
- 458 45 Nunes MC, Mbotwe-Sibanda S, Baillie VL, *et al.* SARS-CoV-2 Omicron Symptomatic Infections in  
459 Previously Infected or Vaccinated South African Healthcare Workers. *Vaccines (Basel)* 2022; **10**: 459.
- 460 46 Powell AA, Kirsebom F, Stowe J, *et al.* Effectiveness of BNT162b2 against COVID-19 in adolescents.  
461 *The Lancet Infectious Diseases* 2022; **22**: 581–3.
- 462 47 Price AM, Olson SM, Newhams MM, *et al.* BNT162b2 Protection against the Omicron Variant in  
463 Children and Adolescents. *New England Journal of Medicine* 2022; **386**: 1899–909.

- 464 48 Ranzani OT, Hitchings MDT, de Melo RL, *et al.* Effectiveness of an inactivated Covid-19 vaccine  
465 with homologous and heterologous boosters against Omicron in Brazil. *Nat Commun* 2022; **13**: 5536.
- 466 49 Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against  
467 Omicron and Delta hospitalisation, a test negative case-control study. *Nat Commun* 2022; **13**: 5736.
- 468 50 Tartof SY, Slezak JM, Puzniak L, *et al.* Durability of BNT162b2 vaccine against hospital and  
469 emergency department admissions due to the omicron and delta variants in a large health system in the  
470 USA: a test-negative case-control study. *The Lancet Respiratory Medicine* 2022a; **10**: 689–99.
- 471 51 Tenforde MW, Self WH, Gaglani M, *et al.* Effectiveness of mRNA Vaccination in Preventing  
472 COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–  
473 January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**. DOI:10.15585/mmwr.mm7112e1.
- 474 52 Tseng HF, Ackerson BK, Luo Y, *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron  
475 and Delta variants. *Nat Med* 2022a; : 1–9.
- 476 53 Young-Xu Y, Zwain GM, Izurieta HS, *et al.* Effectiveness of mRNA COVID-19 vaccines against  
477 Omicron and Delta variants in a matched test-negative case-control study among US veterans. *BMJ*  
478 *Open* 2022; **12**: e063935.
- 479 54 Chariyalertsak S, Intawong K, Chalom K, *et al.* Effectiveness of heterologous 3rd and 4th dose  
480 COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in  
481 Thailand. In Review, 2022 DOI:10.21203/rs.3.rs-1792139/v1.
- 482 55 Link-Gelles R, Levy ME, Gaglani M, *et al.* Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine  
483 Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and  
484 BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June  
485 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**. DOI:10.15585/mmwr.mm7129e1.
- 486 56 Ferdinands JM, Rao S, Dixon BE, *et al.* Waning of vaccine effectiveness against moderate and severe  
487 covid-19 among adults in the US from the VISION network: test negative, case-control study. *BMJ*  
488 2022b; **379**: e072141.
- 489 57 Tseng HF, Ackerson BK, Bruxvoort KJ, *et al.* Effectiveness of mRNA-1273 against infection and  
490 COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4,  
491 and BA.5. 2022b; : 2022.09.30.22280573.
- 492 58 Tartof SY, Slezak JM, Puzniak L, *et al.* BNT162b2 vaccine effectiveness against SARS-CoV-2  
493 omicron BA.4 and BA.5. *The Lancet Infectious Diseases* 2022b; **22**: 1663–5.
- 494 59 Grewal R, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. Effectiveness and Duration of  
495 Protection of a Fourth Dose of Coronavirus Disease 2019 Messenger RNA Vaccine Among Long-term  
496 Care Residents in Ontario, Canada. *The Journal of Infectious Diseases* 2022b; : jiac468.
- 497 60 Intawong K, Chariyalertsak S, Chalom K, *et al.* Effectiveness of heterologous third and fourth dose  
498 COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in  
499 Thailand: A test-negative, case-control study. *Lancet Reg Health Southeast Asia* 2022; : 100121.
- 500 61 Grewal R, Nguyen L, Buchan SA, *et al.* Effectiveness of mRNA COVID-19 vaccine booster doses  
501 against Omicron severe outcomes. 2022c; : 2022.10.31.22281766.

502 62 Nittayasoot N, Suphanchaimat R, Thammawijaya P, *et al.* Real-World Effectiveness of COVID-19  
503 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-  
504 Negative Nationwide Case–Control Study. *Vaccines* 2022; **10**: 2123.

505 63 Gilboa M, Regev-Yochay G, Mandelboim M, *et al.* Durability of immune response after COVID-19  
506 booster vaccination and association with COVID-19 omicron infection. *JAMA network open* 2022; **5**:  
507 e2231778–e2231778.

508 64 Jacobsen H, Jimenez VC, Sitaras I, *et al.* Post-vaccination T cell immunity to omicron. *Frontiers in*  
509 *immunology* 2022; **13**.

510 65 Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, *et al.* Duration of protection of CoronaVac plus  
511 heterologous BNT162b2 booster in the Omicron period in Brazil. *Nature communications* 2022; **13**: 1–  
512 6.

513 66 Wang S, Zhang F, Wang Z, Du Z, Gao C. Reproduction numbers of SARS-CoV-2 Omicron  
514 subvariants. *Journal of Travel Medicine* 2022; **29**: taac108.

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

## 537 **Figure Legend**

538 Figure 1. Overall vaccine effectiveness of full dose against infection or symptomatic infection. Pooled  
539 VE is estimated from all 25 studies combined as well as for each vaccine type. Statistics Cochran's  $Q$ ,  $I^2$   
540 and  $\tau^2$  measure the heterogeneity between studies. End points of the studies are either symptomatic  
541 infection (SI) or any infection (AI). Mixed vaccine type indicates the study reported VEs of these  
542 vaccines combined without distinguishing between them.

543

544 Figure 2. Overall vaccine effectiveness of the first booster dose against infection or symptomatic  
545 infection. Pooled VE is estimated from all 31 studies combined as well as for each vaccine type. Statistics  
546 Cochran's  $Q$ ,  $I^2$  and  $\tau^2$  measure the heterogeneity between studies. End points of the studies are either  
547 symptomatic infection (SI) or any infection (AI). Mixed vaccine type indicates the study reported VEs of  
548 these vaccines combined without distinguishing between them.

549


550 Figure 3. Overall vaccine effectiveness of the second booster dose against infection or symptomatic  
551 infection and against severe events. Pooled VE estimates are stratified by short-term (<60 days) vs. long-  
552 term ( $\geq 60$  days). Statistics Cochran's  $Q$ ,  $I^2$  and  $\tau^2$  measure the heterogeneity between studies. For  
553 infection, possible end points of the studies are symptomatic infection (SI) or any infection (AI). For  
554 severe events, possible end points are hospitalization (H), death (D), severe outcomes (SO) or invasive  
555 procedures (INV). Mixed vaccine type indicates the study reported VEs of these vaccines combined  
556 without distinguishing between them.

557

558 Figure 4. Overall vaccine effectiveness of full dose against severe events. Pooled VE is estimated from  
559 all 24 studies combined as well as for each vaccine type. Statistics Cochran's  $Q$ ,  $I^2$  and  $\tau^2$  measure the  
560 heterogeneity between studies. Possible end points of the studies are hospitalization (H), hospitalization  
561 or death (H/D), emergency department or urgent care encounter (ED/UC), or hospital admissions from  
562 emergency care (EC $\rightarrow$ H). Mixed vaccine type indicates the study reported VEs of these vaccines  
563 combined without distinguishing between them.


564

565 Figure 5. Overall vaccine effectiveness of the first booster dose against severe events. Pooled VE is  
566 estimated from all 28 studies combined as well as for each vaccine type. Statistics Cochran's  $Q$ ,  $I^2$  and  $\tau^2$   
567 measure the heterogeneity between studies. Possible end points of the studies are hospitalization (H),  
568 hospitalization or death (H/D), emergency department or urgent care encounter (ED/UC), or hospital  
569 admissions from emergency care (EC $\rightarrow$ H). Mixed vaccine type indicates the study reported VEs of these  
570 vaccines combined without distinguishing between them.




SI: symptomatic infection; AI: all infection; Mixed: the study reported VEs of these vaccines combined without distinguishing between them.

Figure 1. Overall vaccine effectiveness of full doses against infection or symptomatic infection




SI: symptomatic infection; AI: all infection; Mixed: the study reported VEs of these vaccines combined without distinguishing between them.

Figure 2 Overall vaccine effectiveness of first booster dose against infection or symptomatic infection




SI: symptomatic infection; AI: any infection; ED/UC: emergency department or urgent care encounter; Mixed: the study reported VEs of these vaccines combined without distinguishing between them; H: hospitalization; D: death; SO: severe outcomes; INV: invasive

Figure 3 Overall vaccine effectiveness of second booster dose against Infection or symptomatic infection and against severe events



H: hospitalization; H/D: hospitalization or death; ED/UC: emergency department or urgent care encounter; EC→H: hospital admissions from emergency care; Mixed: the study reported VEs of these vaccines combined without distinguishing between them; NR: not reported

Figure 4 Overall vaccine effectiveness of full dose against severe events



H: hospitalization; H/D: hospitalization or death; ED/UC: emergency department or urgent care encounter; EC→H: hospital admissions from emergency care; Mixed: the study reported VEs of these vaccines combined without distinguishing between them

Figure 5 Overall vaccine effectiveness of first booster dose against severe events